Table 1 Profile of patients on dialysis and case-fatality overall and across years of the study
Variables | Overall | 2002–2004 | 2005–06 | 2007–08 | 2009–10 | 2011–12 | p-value1 | p-trend2 | p year*gender3 |
|---|---|---|---|---|---|---|---|---|---|
N (%) | 661 (100) | 120 (18.1) | 153 (23.1) | 111 (16.8) | 156 (23.6) | 121 (18.3) | |||
Men, n (%) | 436 (66.0) | 83 (69.2) | 103 (67.3) | 77 (69.4) | 96 (61.5) | 77 (63.6) | 0.575 | 0.187 | NA |
Mean age, years (SD) | 46.3 (14.7) | 46.9 (15.7) | 48.3 (13.5) | 44.9 (16.4) | 45.2 (14.0) | 46.1 (14.5) | 0.282 | 0.133 | 0.840 |
Mean haemoglobin, g/dl (SD) | 7.7 (2.0) | 7.4 (2.3) | 7.6 (1.9) | 7.9 (1.8) | 7.5 (1.9) | 7.9 (1.9) | 0.240 | 0.521 | 0.649 |
Mean Urea, g/l (SD) | 2.60 (1.16) | 2.28 (0.96) | 2.48 (1.17) | 2.67 (1.20) | 2.74 (1.91) | 2.8 (1.1) | 0.009 | 0.003 | 0.661 |
Mean creatinine, mg/l (SD) | 184.3 (88.9) | 168.5 (87.5) | 191.7 (104.8) | 188.9 (87.3) | 184.2 (82.2) | 185.1 (75.1) | 0.428 | 0.267 | 0.702 |
Mean corrected calcium, mg/l (SD) | 80.2 (13.7) | 79.6 (14.0) | 80.9 (13.7) | 82.0 (11.4) | 80.9 (13.2) | 77.6 (15.6) | 0.411 | 0.523 | 0.829 |
Mean phosphate, mg/l (SD) | 72.6 (35.2) | 85.4 (55.2) | 66.0 (30.1) | 75.6 (28.0) | 66.4 (31.1) | 78.2 (33.7) | 0.020 | 0.037 | 0.270 |
Planned dialysis start, n (%) | 74 (11.2) | 8 (6.7) | 16 (10.5) | 7 (6.3) | 23 (14.8) | 20 (16.5) | 0.031 | 0.007 | 0.518 |
Median dialysis duration, days (Q1-Q3) | 187 [37–754] | 15 [6–298] | 197 [44–836] | 218 [57–855] | 580 [119–977] | 179 [62–357] | <0.0001 | 0.630 | 0.173 |
Background nephropathy, n (%) | 0.622 | NA | 0.328 | ||||||
Hypertension | 187 (28.3) | 35 (29.2) | 40 (26.1) | 37 (33.3) | 40 (25.6) | 35 (28.9) | |||
Diabetes | 92 (13.9) | 16 (13.3) | 19 (12.4) | 18 (16.2) | 21 (13.5) | 18 (14.9) | |||
Hypertension and diabetes | 48 (7.3) | 10 (8.3) | 11 (12.4) | 8 (7.2) | 10 (6.4) | 9 (7.4) | |||
Chronic glomerulonephritis | 116 (17.5) | 13 (10.8 | 27 (17.6) | 25 (22.5) | 34 (21.8) | 17 (14.0) | |||
HIV | 44 (6.7) | 8 (6.7) | 11 (7.2) | 5 (4.5) | 10 (6.4) | 10 (8.3) | |||
Others | 62 (9.4) | 9 (7.5) | 18 (7.2) | 8 (7.2) | 16 (10.3) | 11 (9.1) | |||
Unknown | 112 (16.9) | 29 (21.2) | 27 (17.6) | 10 (9.0) | 25 (16.0) | 21 (17.4) | |||
Median Charlson Score (Q1-Q3) | 1 [1–2] | 1 [1–2] | 1 [1–2] | 1 [1–1] | 1 [1–1] | 1 [1–2] | 0.044 | 0.007 | 0.751 |
Death overall, n (%) | 297 (44.9) | 27 (22.5) | 98 (64.0) | 55 (49.5) | 68 (43.6) | 49 (40.5) | <0.0001 | 0.508 | 0.212 |
Death at 12 month, n (%) | 177 (26.8) | 9 (7.5) | 57 (37.2) | 33 (29.7) | 34 (21.8) | 44 (36.4) | <0.0001 | 0.004 | 0.138 |
Death by follow-up duration | <0.0001 | NA | 0.475 | ||||||
< 120 days | 101 (15.3) | 8 (6.7) | 32 (20.9) | 20 (18.0) | 20 (12.8) | 21 (17.4) | |||
120–365 | 76 (11.5) | 1 (0.8) | 25 (16.4) | 13 (11.7) | 14 (9.0) | 23 (19.0) | |||
> 365 | 120 (18.1) | 18 (15.0) | 41 (26.8) | 22 (19.8) | 34 (21.8) | 5 (4.1) |